Pourmatroud 2012.

Methods	Randomised controlled trial involving 102 participants: 52 participants in received ascorbic acid and 50 participants received no treatment Setting: Tertiary hospital in Ahvaz, Iran From October 2009 to August 2010, women (n = 102) of reproductive age who were admitted for an abdominal myomectomy were randomly assigned to receive either ascorbic acid to no treatment No power calculation performed
Participants	At least one non‐cavitary fibroma ≥ 40 mm2 in size; a normal coagulation profile; non‐smoker; no history of chronic illness (renal failure, drug abuse, haemoglobinopathy or respiratory, liver or heart disease); no history of recent hospitalization; regular consumption of fresh fruit or vegetables at least once a day and no history of glucose 6‐phophatase dehydrogenase deficiency. Baseline characteristics were similar in both groups Ethnicity not described
Interventions	Intervention group received ascorbic acid 500mg in 15ml normal saline at a rate of 50ug/min, first ampoule of 500mg ascorbic acid given after reaching the uterus and before myomectomy, the second administered during myoma enucleation and the third during wound closure. After the operation, two additional ascorbic acid ampoules were infused at a rate of 20ug/min over the first 12h. Control group received no treatment. In both groups, myomectomy was performed by laparotomy
Outcomes	The outcomes measured were the size and number of myoma, duration of the operation, blood loss, haemoglobin and haematocrit 6h after the operation, blood transfusion, and other complications. Blood loss was measured by adding the blood collected via suction with the number of soaked surgical 4X4 gauze (each one assigned a value of 5 ml blood) and towels (each one was assigned a value of 50 ml blood)
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Participants described as ‘randomly assigned’ to the intervention and control groups. No details given on the method of random sequence generation
Allocation concealment (selection bias)	Unclear risk	No details given on the method of allocation concealment
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete outcome data
Selective reporting (reporting bias)	Unclear risk	We do not have access to the study protocol
Other bias	Low risk	No other sources of bias identified
Blinding of participants and personnel (performance bias) All outcomes	High risk	It is described that the surgical team was blinded, but no information given on the blinding of study participants. However the control group did not receive an identical placebo
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided